Technical Analysis for IVVD - Invivyd, Inc.

Grade Last Price % Change Price Change
F 0.91 2.36% 0.02
IVVD closed up 2.36 percent on Friday, November 1, 2024, on 85 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 7
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction 2.36%
NR7 Range Contraction 2.36%
Narrow Range Bar Range Contraction 2.36%
Stochastic Reached Oversold Weakness 2.36%
Oversold Stochastic Weakness 2.36%
Bollinger Band Squeeze Range Contraction 0.38%
Inside Day Range Contraction 0.38%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 23 hours ago
Outside Day about 23 hours ago
Up 3% about 23 hours ago
Up 2% about 23 hours ago
Up 1% about 23 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Invivyd, Inc. Description

Invivyd, formerly Adagio Therapeutics (Nasdaq: ADGI), is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases.​ The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. ​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape.​ The company is generating a robust pipeline of products for use in both prevention and treatment of disease. NVD200, Invivyd’s first antibody combination product for COVID-19, is expected to enter the clinic in Q1 2023. ​ Invivyd’s most advanced pipeline candidate is adintrevimab, an investigational monoclonal antibody which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Adintrevimab is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. The company also has multiple discovery stage candidates for the prevention of seasonal influenza.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Immunology Antibodies Monoclonal Antibodies Antibody Viral Disease Seasonal Influenza Symphogen

Is IVVD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 5.195
52 Week Low 0.8116
Average Volume 480,507
200-Day Moving Average 2.18
50-Day Moving Average 0.99
20-Day Moving Average 0.96
10-Day Moving Average 0.97
Average True Range 0.08
RSI (14) 44.75
ADX 17.79
+DI 16.17
-DI 17.09
Chandelier Exit (Long, 3 ATRs) 0.82
Chandelier Exit (Short, 3 ATRs) 1.13
Upper Bollinger Bands 1.07
Lower Bollinger Band 0.86
Percent B (%b) 0.26
BandWidth 21.96
MACD Line -0.02
MACD Signal Line -0.01
MACD Histogram -0.0082
Fundamentals Value
Market Cap 100.6 Million
Num Shares 110 Million
EPS -1.55
Price-to-Earnings (P/E) Ratio -0.59
Price-to-Sales 0.00
Price-to-Book 2.25
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.99
Resistance 3 (R3) 0.99 0.97 0.98
Resistance 2 (R2) 0.97 0.95 0.97 0.97
Resistance 1 (R1) 0.94 0.93 0.95 0.94 0.97
Pivot Point 0.91 0.91 0.92 0.91 0.91
Support 1 (S1) 0.89 0.90 0.90 0.89 0.86
Support 2 (S2) 0.86 0.88 0.86 0.85
Support 3 (S3) 0.84 0.86 0.85
Support 4 (S4) 0.84